The global Bispecific T Cell Engager Therapeutics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes. Bispecific T cell-engagers (BiTEs) are small antibody-based molecules composed of two antigen-binding single-chain variable fragments (scFvs) genetically fused by a flexible peptide linker and capable of redirecting T cells against tumour-associated antigen (TAA)-bearing cancer cells.By binding T cells and tumor cells through the specific structure, bispecific T cell engagers enhance tumor lysis effectually and provide relapse/refractory patients with feasible options regardless of mutations or T cell dysfunction.
This report aims to provide a comprehensive presentation of the global market for Bispecific T Cell Engager Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bispecific T Cell Engager Therapeutics. This report contains market size and forecasts of Bispecific T Cell Engager Therapeutics in global, including the following market information:
Global Bispecific T Cell Engager Therapeutics Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global top five companies in 2022 (%)
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Heavy Chains Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Bispecific T Cell Engager Therapeutics include LAVA, Amgen, Takeda, Merck, Nk pharma, Seagen Inc. and BPS Bioscience, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Bispecific T Cell Engager Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Bispecific T Cell Engager Therapeutics Market, by Type, 2018-2023, 2024-2032 ($ millions)
Global Bispecific T Cell Engager Therapeutics Market Segment Percentages, by Type, 2022 (%)
- Heavy Chains
- Light Chains
Global Bispecific T Cell Engager Therapeutics Market, by Application, 2018-2023, 2024-2032 ($ millions)
Global Bispecific T Cell Engager Therapeutics Market Segment Percentages, by Application, 2022 (%)
- Hospital
- Laboratorios
- Others
Global Bispecific T Cell Engager Therapeutics Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions)
Global Bispecific T Cell Engager Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Bispecific T Cell Engager Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Bispecific T Cell Engager Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- LAVA
- Amgen
- Takeda
- Merck
- Nk pharma
- Seagen Inc.
- BPS Bioscience
Outline of Major Chapters:
Chapter 1: Introduces the definition of Bispecific T Cell Engager Therapeutics, market overview.
Chapter 2: Global Bispecific T Cell Engager Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Bispecific T Cell Engager Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Bispecific T Cell Engager Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Bispecific T Cell Engager Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Bispecific T Cell Engager Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Bispecific T Cell Engager Therapeutics Overall Market Size
2.1 Global Bispecific T Cell Engager Therapeutics Market Size: 2022 VS 2032
2.2 Global Bispecific T Cell Engager Therapeutics Market Size, Prospects & Forecasts: 2018-2032
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Bispecific T Cell Engager Therapeutics Players in Global Market
3.2 Top Global Bispecific T Cell Engager Therapeutics Companies Ranked by Revenue
3.3 Global Bispecific T Cell Engager Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Bispecific T Cell Engager Therapeutics Companies in Global Market, by Revenue in 2022
3.5 Global Companies Bispecific T Cell Engager Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Bispecific T Cell Engager Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Bispecific T Cell Engager Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Bispecific T Cell Engager Therapeutics Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Bispecific T Cell Engager Therapeutics Market Size Markets, 2022 & 2032
4.1.2 Heavy Chains
4.1.3 Light Chains
4.2 By Type - Global Bispecific T Cell Engager Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Bispecific T Cell Engager Therapeutics Revenue, 2018-2023
4.2.2 By Type - Global Bispecific T Cell Engager Therapeutics Revenue, 2024-2032
4.2.3 By Type - Global Bispecific T Cell Engager Therapeutics Revenue Market Share, 2018-2032
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Bispecific T Cell Engager Therapeutics Market Size, 2022 & 2032
5.1.2 Hospital
5.1.3 Laboratorios
5.1.4 Others
5.2 By Application - Global Bispecific T Cell Engager Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Bispecific T Cell Engager Therapeutics Revenue, 2018-2023
5.2.2 By Application - Global Bispecific T Cell Engager Therapeutics Revenue, 2024-2032
5.2.3 By Application - Global Bispecific T Cell Engager Therapeutics Revenue Market Share, 2018-2032
6 Sights by Region
6.1 By Region - Global Bispecific T Cell Engager Therapeutics Market Size, 2022 & 2032
6.2 By Region - Global Bispecific T Cell Engager Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Bispecific T Cell Engager Therapeutics Revenue, 2018-2023
6.2.2 By Region - Global Bispecific T Cell Engager Therapeutics Revenue, 2024-2032
6.2.3 By Region - Global Bispecific T Cell Engager Therapeutics Revenue Market Share, 2018-2032
6.3 North America
6.3.1 By Country - North America Bispecific T Cell Engager Therapeutics Revenue, 2018-2032
6.3.2 US Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.3.3 Canada Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.3.4 Mexico Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.4 Europe
6.4.1 By Country - Europe Bispecific T Cell Engager Therapeutics Revenue, 2018-2032
6.4.2 Germany Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.4.3 France Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.4.4 U.K. Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.4.5 Italy Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.4.6 Russia Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.4.7 Nordic Countries Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.4.8 Benelux Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.5 Asia
6.5.1 By Region - Asia Bispecific T Cell Engager Therapeutics Revenue, 2018-2032
6.5.2 China Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.5.3 Japan Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.5.4 South Korea Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.5.5 Southeast Asia Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.5.6 India Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.6 South America
6.6.1 By Country - South America Bispecific T Cell Engager Therapeutics Revenue, 2018-2032
6.6.2 Brazil Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.6.3 Argentina Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Bispecific T Cell Engager Therapeutics Revenue, 2018-2032
6.7.2 Turkey Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.7.3 Israel Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.7.4 Saudi Arabia Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
6.7.5 UAE Bispecific T Cell Engager Therapeutics Market Size, 2018-2032
7 Bispecific T Cell Engager Therapeutics Companies Profiles
7.1 LAVA
7.1.1 LAVA Company Summary
7.1.2 LAVA Business Overview
7.1.3 LAVA Bispecific T Cell Engager Therapeutics Major Product Offerings
7.1.4 LAVA Bispecific T Cell Engager Therapeutics Revenue in Global Market (2018-2023)
7.1.5 LAVA Key News & Latest Developments
7.2 Amgen
7.2.1 Amgen Company Summary
7.2.2 Amgen Business Overview
7.2.3 Amgen Bispecific T Cell Engager Therapeutics Major Product Offerings
7.2.4 Amgen Bispecific T Cell Engager Therapeutics Revenue in Global Market (2018-2023)
7.2.5 Amgen Key News & Latest Developments
7.3 Takeda
7.3.1 Takeda Company Summary
7.3.2 Takeda Business Overview
7.3.3 Takeda Bispecific T Cell Engager Therapeutics Major Product Offerings
7.3.4 Takeda Bispecific T Cell Engager Therapeutics Revenue in Global Market (2018-2023)
7.3.5 Takeda Key News & Latest Developments
7.4 Merck
7.4.1 Merck Company Summary
7.4.2 Merck Business Overview
7.4.3 Merck Bispecific T Cell Engager Therapeutics Major Product Offerings
7.4.4 Merck Bispecific T Cell Engager Therapeutics Revenue in Global Market (2018-2023)
7.4.5 Merck Key News & Latest Developments
7.5 Nk pharma
7.5.1 Nk pharma Company Summary
7.5.2 Nk pharma Business Overview
7.5.3 Nk pharma Bispecific T Cell Engager Therapeutics Major Product Offerings
7.5.4 Nk pharma Bispecific T Cell Engager Therapeutics Revenue in Global Market (2018-2023)
7.5.5 Nk pharma Key News & Latest Developments
7.6 Seagen Inc.
7.6.1 Seagen Inc. Company Summary
7.6.2 Seagen Inc. Business Overview
7.6.3 Seagen Inc. Bispecific T Cell Engager Therapeutics Major Product Offerings
7.6.4 Seagen Inc. Bispecific T Cell Engager Therapeutics Revenue in Global Market (2018-2023)
7.6.5 Seagen Inc. Key News & Latest Developments
7.7 BPS Bioscience
7.7.1 BPS Bioscience Company Summary
7.7.2 BPS Bioscience Business Overview
7.7.3 BPS Bioscience Bispecific T Cell Engager Therapeutics Major Product Offerings
7.7.4 BPS Bioscience Bispecific T Cell Engager Therapeutics Revenue in Global Market (2018-2023)
7.7.5 BPS Bioscience Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Bispecific T Cell Engager Therapeutics Market Opportunities & Trends in Global Market
Table 2. Bispecific T Cell Engager Therapeutics Market Drivers in Global Market
Table 3. Bispecific T Cell Engager Therapeutics Market Restraints in Global Market
Table 4. Key Players of Bispecific T Cell Engager Therapeutics in Global Market
Table 5. Top Bispecific T Cell Engager Therapeutics Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Bispecific T Cell Engager Therapeutics Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Bispecific T Cell Engager Therapeutics Revenue Share by Companies, 2018-2023
Table 8. Global Companies Bispecific T Cell Engager Therapeutics Product Type
Table 9. List of Global Tier 1 Bispecific T Cell Engager Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Bispecific T Cell Engager Therapeutics Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2022 & 2032
Table 12. By Type - Bispecific T Cell Engager Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Bispecific T Cell Engager Therapeutics Revenue in Global (US$, Mn), 2024-2032
Table 14. By Application ? Global Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2022 & 2032
Table 15. By Application - Bispecific T Cell Engager Therapeutics Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Bispecific T Cell Engager Therapeutics Revenue in Global (US$, Mn), 2024-2032
Table 17. By Region ? Global Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2022 & 2032
Table 18. By Region - Global Bispecific T Cell Engager Therapeutics Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Bispecific T Cell Engager Therapeutics Revenue (US$, Mn), 2024-2032
Table 20. By Country - North America Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2024-2032
Table 22. By Country - Europe Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2024-2032
Table 24. By Region - Asia Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2024-2032
Table 26. By Country - South America Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2024-2032
Table 28. By Country - Middle East & Africa Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2024-2032
Table 30. LAVA Company Summary
Table 31. LAVA Bispecific T Cell Engager Therapeutics Product Offerings
Table 32. LAVA Bispecific T Cell Engager Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 33. LAVA Key News & Latest Developments
Table 34. Amgen Company Summary
Table 35. Amgen Bispecific T Cell Engager Therapeutics Product Offerings
Table 36. Amgen Bispecific T Cell Engager Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 37. Amgen Key News & Latest Developments
Table 38. Takeda Company Summary
Table 39. Takeda Bispecific T Cell Engager Therapeutics Product Offerings
Table 40. Takeda Bispecific T Cell Engager Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 41. Takeda Key News & Latest Developments
Table 42. Merck Company Summary
Table 43. Merck Bispecific T Cell Engager Therapeutics Product Offerings
Table 44. Merck Bispecific T Cell Engager Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 45. Merck Key News & Latest Developments
Table 46. Nk pharma Company Summary
Table 47. Nk pharma Bispecific T Cell Engager Therapeutics Product Offerings
Table 48. Nk pharma Bispecific T Cell Engager Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 49. Nk pharma Key News & Latest Developments
Table 50. Seagen Inc. Company Summary
Table 51. Seagen Inc. Bispecific T Cell Engager Therapeutics Product Offerings
Table 52. Seagen Inc. Bispecific T Cell Engager Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 53. Seagen Inc. Key News & Latest Developments
Table 54. BPS Bioscience Company Summary
Table 55. BPS Bioscience Bispecific T Cell Engager Therapeutics Product Offerings
Table 56. BPS Bioscience Bispecific T Cell Engager Therapeutics Revenue (US$, Mn) & (2018-2023)
Table 57. BPS Bioscience Key News & Latest Developments
List of Figures
Figure 1. Bispecific T Cell Engager Therapeutics Segment by Type in 2022
Figure 2. Bispecific T Cell Engager Therapeutics Segment by Application in 2022
Figure 3. Global Bispecific T Cell Engager Therapeutics Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Bispecific T Cell Engager Therapeutics Market Size: 2022 VS 2032 (US$, Mn)
Figure 6. Global Bispecific T Cell Engager Therapeutics Revenue, 2018-2032 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Bispecific T Cell Engager Therapeutics Revenue in 2022
Figure 8. By Type - Global Bispecific T Cell Engager Therapeutics Revenue Market Share, 2018-2032
Figure 9. By Application - Global Bispecific T Cell Engager Therapeutics Revenue Market Share, 2018-2032
Figure 10. By Type - Global Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2022 & 2032
Figure 11. By Type - Global Bispecific T Cell Engager Therapeutics Revenue Market Share, 2018-2032
Figure 12. By Application - Global Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2022 & 2032
Figure 13. By Application - Global Bispecific T Cell Engager Therapeutics Revenue Market Share, 2018-2032
Figure 14. By Region - Global Bispecific T Cell Engager Therapeutics Revenue Market Share, 2018-2032
Figure 15. By Country - North America Bispecific T Cell Engager Therapeutics Revenue Market Share, 2018-2032
Figure 16. US Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 17. Canada Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 18. Mexico Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 19. By Country - Europe Bispecific T Cell Engager Therapeutics Revenue Market Share, 2018-2032
Figure 20. Germany Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 21. France Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 22. U.K. Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 23. Italy Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 24. Russia Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 25. Nordic Countries Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 26. Benelux Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 27. By Region - Asia Bispecific T Cell Engager Therapeutics Revenue Market Share, 2018-2032
Figure 28. China Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 29. Japan Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 30. South Korea Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 31. Southeast Asia Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 32. India Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 33. By Country - South America Bispecific T Cell Engager Therapeutics Revenue Market Share, 2018-2032
Figure 34. Brazil Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 35. Argentina Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 36. By Country - Middle East & Africa Bispecific T Cell Engager Therapeutics Revenue Market Share, 2018-2032
Figure 37. Turkey Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 38. Israel Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 39. Saudi Arabia Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 40. UAE Bispecific T Cell Engager Therapeutics Revenue, (US$, Mn), 2018-2032
Figure 41. LAVA Bispecific T Cell Engager Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Amgen Bispecific T Cell Engager Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Takeda Bispecific T Cell Engager Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Merck Bispecific T Cell Engager Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Nk pharma Bispecific T Cell Engager Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Seagen Inc. Bispecific T Cell Engager Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. BPS Bioscience Bispecific T Cell Engager Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
